Credit Suisse’s Abiomed Inc ABMD Stock Holding History

Credit Suisse’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-23,800	Closed	-$7.43M	–	4621
2021 Q2	$7.43M	Buy	+23,800	New	+$7.3M	﹤0.01%	1762
2020 Q4	–	Sell	-19,400	Closed	-$5.38M	–	4489
2020 Q3	$5.38M	Buy	+19,400	New	+$5.59M	﹤0.01%	1756

Other funds holding ABMD

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Credit Suisse's ABMD Position: Q4 2022 in Review

Credit Suisse sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 353,961 shares — an estimated $87M sold.

Credit Suisse first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $289M in Q1 2021. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

Credit Suisse reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
Credit Suisse sold 353,961 Abiomed Inc shares in Q4 2022, an estimated $87M.
Credit Suisse first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
Credit Suisse's Abiomed Inc position peaked at $289M in Q1 2021.
8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Credit Suisse's 13F filing for Q4 2022, filed 13 Feb 2023.